Table 3.
Univariate analysis of the impact of various parameters on overall survival and time to progression for the whole cohort
|
Overall survival
|
Time to progression
|
|||
|---|---|---|---|---|
| Variable | HR | P | HR | P |
| Sex | 0.77 | .18 | 0.78 | .10 |
| β2-microglobulin level, μg/mL | 1.112 | .003 | 1.052 | .11 |
| LDH level, U/L | 1.003 | < .001 | 1.001 | .39 |
| PCLI, % | 1.197 | < .001 | 1.133 | < .001 |
| BMPC, % | 1.016 | < .001 | 1.019 | < .001 |
| Durie-Salmon stage | 1.685 | .017 | 1.512 | .012 |
| Abnormal cytogenetics | 2.275 | < .001 | 2.394 | < .001 |
| Disease status at transplantation, relapse vs plateau | 1.238 | < .001 | 1.27 | < .001 |
| Response, other vs CR | 1.372 | .14 | 2.05 | < .001 |
| Circulating myeloma cells | ||||
| Continuous | 1.001 | .008 | 1.001 | .031 |
| Nominal | 1.62 | .009 | 1.60 | .001 |
HR indicates hazard ratio; LDH, lactate dehydrogenase; PCLI bone marrow plasma-cell labeling index; and BMPC refers to the percentage of bone marrow plasma cells.